Off-target effects of glycoprotein IIb/IIIa receptor inhibitors.

Off-target effects of glycoprotein IIb/IIIa receptor inhibitors. Cardiol J. 2014 Feb 14; Authors: Ostrowska M, Adamski P, Koziński M, Navarese EP, Fabiszak T, Grześk G, Paciorek P, Kubica J Abstract Soon after identification of the platelet membrane glycoprotein (GP) IIb/IIIa receptor and due to its key role in platelet aggregation, it became the target of antithrombotic therapy. There are three intravenous glycoprotein IIb/IIIa receptor inhibitors (GPI) used in clinical practice, particularly in patients with acute coronary syndrome undergoing percutaneous coronary intervention. The aim of the current review is to summarize available knowledge concerning off-target effects of GPI. All three drugs have similar antithrombotic properties, but differ with respect to pharmocodynamics, pharmacokinetics and off-target effects. Eptifibatide and tirofiban are highly specific GP IIb/IIIa inhibitors, while abciximab is unselective and also cross-reacts with the integrin αvβ3 - the vitronectin receptor and leukocyte-associated integrin Mac-1. As a result abciximab seems to reduce the development of clinical restenosis, decrease the infarct size, inhibit the adhesion to medical steel and modulate the inflammatory response. The intracoronary administration of abciximab provides higher drug concentration in the target area, increasing dose-dependent interactions with other integrins. Off-target effects of small molecule GPI eptifibatide and tirofiban ar...
Source: Cardiology Journal - Category: Cardiology Authors: Tags: Cardiol J Source Type: research